Yearbook 2017

 

Embed or link this publication

Description

Yearbook 2017

Popular Pages


p. 1



[close]

p. 2



[close]

p. 3

Editorial 1 EFMC YEARBOOK 2017 Dear colleagues, In 2017 I will be entering the third and final year of my EFMC presidency. Time flies and the work is not yet finished, but I am convinced that with the help and enthusiasm of many collaborators, we will continue to build the success story of our federation. During the past two years I could always count on the support of the Executive Committee members and especially the help of Brieuc Matagne from the EFMC administrative secretariat and the other members of the team of Ly Differding was crucial. I would also like to take the opportunity to welcome Anders Karlèn as Secretary and Antoni Torrens and Matt Tozer as EC Members. I am very much looking forward to work with Anders, Toni, Matt and the other EC Members in this upcoming year: Yves Auberson (President Elect), Pascal George (Treasurer), Rui Moreira (EC Member) and Henk Timmerman (EFMC Advisor). A special word of thanks goes to Uli Stilz, who is leaving the Executive Committee as Past President. I am sure that everyone will agree with me that Uli played a very important role in organising a workshop in Frankfurt that helped reshaping EFMC and redefining our mission. During his presidency I was Secretary and I always appreciated the efficient and friendly collaboration with Uli. Uli, I wish you all the best for your future life and I am sure that EFMC will be able to continue to count on your advise and experience. Many thanks also to Jordi Gracia, who decided not to continue as Secretary because of other professional commitments. Jordi, during the past two years we had many interactions and I was always impressed by your helpful, calm and friendly approach. I would like to wish you all the best for the future. Let me also thank Antonello Mai, leaving EC Member for his engagement and support to the Executive Committee over the last years. Your contributions were always highly appreciated and I wish you all the best with your future career. I would also like to thank Anders Karlèn for his contribution to the Council, and welcome Annika Jenmalm Jensen as new Council Members. I have now the pleasure to provide you, through this editorial, with an overview of important events in 2016 and planned activities of our Federation in 2017. The main EFMC event in 2016 was of course our flagship event, the XXIV EFMC International Symposium on Medicinal Chemistry which took place in Manchester (United Kingdom) on August 27-September 1, 2016. Organised by the Biological and Medicinal Chemistry Sector (BMCS) of the Royal Society of Chemistry, on behalf of the European Federation for Medicinal Chemistry (EFMC), EFMC-ISMC 2016 brought together more than 1000 scientists coming from 50 different nations who exchanged ideas, discussed hot topics and enlarged their networks. This biennial meeting is a key symposium in its field and attracts a highly targeted audience composed of experts in drug discovery and development, covering recent progress in drug research in major therapeutic areas. EFMC-ISMC 2016 also presented the most recent advances in lead identification and optimization strategies, drug design and profiling technologies. The impact of biomarkers and imaging at the interfaces between chemistry, biology and experimental medicine was illustrated. This edition, a particular emphasis has been put on first time disclosures, recent highlights in medicinal chemistry, and the

[close]

p. 4

2 Editorial impact of novel organic synthesis in drug discovery. In Manchester, we also reached out to the general public with the organisation of a press conference and a public event in the Manchester Museum of Science and Industry. I am most thankful to Phil Jones and all members of the international and local organising committee for having organised this fantastic key event for EFMC. EFMC organised this year again the EFMC Young Medicinal Chemist Symposium (EFMCYMCS) on Thursday and Friday, September 1-2, 2016 as a satellite event of XXIV EFMC International Symposium on Medicinal Chemistry. The symposium consolidated its aim to create a network of young European scientists in Medicinal Chemistry, to stimulate young European investigators in Medicinal Chemistry to share their scientific work with peers and inspiring leaders in the field, and to create competition and excellence in Medicinal Chemistry within Europe. I am particularly glad that the increasing success of this event led the organisers to extend its duration from a one day event to a one and a half day mini-Symposium, giving an opportunity to more and more young and promising medicinal chemists to present their work. EFMC is grateful to Mike Warring and his team for having put together an interesting programme which attracted more than 120 participants at the Manchester Institute of Biotechnology. With the aim to support training and networking within the medicinal chemistry community, EFMC also continued to organise the EFMC Short Courses. In April 2016, Gerhard Müller and Anita Wegert (Mercachem, The Netherlands) organised a course on “Modulation of Enzymes; Epigenetics and Beyond”. I am grateful to Gerhard, Anita and Henk for helping EFMC in fulfilling the important mandate to support the education and training of today’s medicinal chemists, and would like to thank them for their efforts. In 2017, EFMC will continue its tradition of organising Short Courses. The Course on “A Matter of Time; A Kinetic Perspective on Drug-Target Interactions” is scheduled for April 23-26, 2017 and will be organised by Ad IJzerman and Laura Heitman (Leiden University, The Netherlands). Detailed information can be found on the website www.efmcshortcourses.org In the course of 2016, EFMC strengthened its partnership with EuCheMS by becoming a supporting Member, and created new partnerships by signing a Memorandum of Understanding with the Chinese Pharmaceutical Association (CPA). EFMC and EuCheMS have always sustained a fruitful collaboration in the form of an exchange of sessions at the main event of the respective association, and further developed their partnership in 2016 with the organisation of a STOA Working Breakfast on “Solving Antibiotic Resistance” with the intention to convince policy makers in the EU of the urgent need to invest in the discovery of novel antibiotics. Jointly, we also nominated candidates for the EU Open Science Policy Platform. In 2017, EFMC will co-organise three international meetings to encourage contacts and exchanges between medicinal chemists in Europe and around the world: The 6th edition of the Frontiers in Medicinal Chemistry Symposium, now rebranded as ACSMEDI-EFMC Medicinal Chemistry Frontiers will be held on June 25-28, 2017 in Philadelphia, United States. This event is organised on a biennial basis, as a collaboration between the ACS MediDivision and the EFMC. Following the everlasting spirit of

[close]

p. 5

Editorial 3 EFMC YEARBOOK 2017 the series, the meeting will bring together top quality speakers from the US and Europe. The 7th edition of the EFMC International Symposium on Advances in Synthetic and Medicinal Chemistry (EFMC-ASMC’17) will take place in Vienna on August 27-31, 2017 and will be jointly organised by the EFMC, the Medicinal Chemistry Section of the Austrian Chemical Society (GÖCH), ChemBridge Corporation and LD Organisation. Previously organised in Russia and in Ukraine, and after a trip to Israel for the last edition, this edition and the next ones will now be organised in one of the 23 countries covered by an EFMC National Adhering Organisation. This edition of the EFMC-ASMC will once again gather distinguished academic and industrial speakers from both Medicinal and Organic Chemistry. years ago. The call for the 2017 Awards and Prizes are open, and I would like to encourage you to submit nominations before the deadline of January 31. Over the coming year we will continue to provide you with updates on EFMC activities through our monthly newsletter MedChemWatch, via the EFMC LinkedIn group, via Twitter and on our regularly updated website www.efmc.info, which offers also a meeting calendar and a job portal. Furthermore, MedChemComm, the EFMC journal published in collaboration with RSC, is released monthly and I would like to stimulate all of you to submit your high quality papers. Let me close by wishing you all the best for a splendid 2017, both in your professional and personal life. Finally, in connection with the EFMC-ASMC’17, the 4th edition of the EFMC Young Medicinal Chemist Symposium will also take place in Vienna, Austria on September 1-2, 2017, hoping to attract more and more young participants as speakers or attendees. I do hope to be able to welcome a great number of you to one of those events. With my very best personal regards, Koen Augustyns EFMC President The European Federation for Medicinal Chemistry also rewarded scientific excellence. The prestigious EFMC Awards, conferred on the occasion of the XXIV EFMC International Symposium on Medicinal Chemistry were awarded to François Diederich, Paul Hergenrother and Jan Steyaert. EFMC Prizes to acknowledge the scientific accomplishments of young medicinal chemists, both in industry and academia were also conferred at the same occasion to Jean Quancard and Frank Boeckler. These EFMC prizes are given annually and are restricted to scientists who completed their PhD twelve or less

[close]

p. 6



[close]

p. 7

EFMC YEARBOOK 2017 Table of Contents EFMC Presentation Editorial Table of Contents Sponsors Corporate Members Executive Committee Council Advisory Board EFMC Framework MedChemWatch EFMC Objectives Report EFMC-ISMC 2016 Report EFMC-YMCS 2016 EFMC Awards EFMC Prizes Calendar of Events EFMC Short Courses National Adhering Organisations Austria Belgium Croatia Denmark Finland France Germany Greece Hungary Israel Italy Latvia Poland Portugal Russia Serbia Slovenia Spain Sweden Switzerland The Netherlands Turkey United Kingdom Directory of Companies Directory of Companies 1 5 6 6 7 8 9 10 12 13 15 17 20 22 24 33 37 38 40 41 42 43 44 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 65 5 Medicinal Chemistry in Europe, the Yearbook of the European Federation for Medicinal Chemistry is published by: LD Organisation sprl Scientific Conference Producers Rue Michel de Ghelderode 33/2 - BE-1348 Louvain-la-Neuve, Belgium Tel: +32 10 45 47 77 - Fax: +32 10 45 97 19 administration@efmc.info Reproduction: All items published in this directory are protected by copyright. Reproduction by reprint, photocopy, microfilm or any other process is not allowed without the prior written permission of the publisher. www.efmc.info

[close]

p. 8

Sponsors 6 CProermpiourmateSpSopnosnosrors CHEMBRIDGE CORPORATION Corporate Members Premium Sponsors are CROs, Service Providers, Publishers that directly sponsor EFMC activities through major financial contributions. Their contribution helps the EFMC towards its main objective of developing a strong Medicinal Chemistry community in Europe that is wellequipped for the challenges of the future and enables the discovery of innovative new medicines for patients. EFMC offers any company involved in life sciences the opportunity to become an official corporate member. Corporate membership will help EFMC with its objective of advancing the science of medicinal chemistry and can be achieved in several ways: - By sponsoring an EFMC International Symposium with a minimum of €10 000 - By sponsoring an official EFMC Award - By paying an annual fee of € 2 000 to EFMC Companies interested in becoming a corporate member should contact the Administrative Secretariat at administration@efmc.info BAYER NAUTA FOUNDATION F.HOFFMANN-LA ROCHE BOEHRINGER INGELHEIM NOVARTIS SERVIER JANSSEN R&D PFIZER UCB MERCK PROUS INSTITUTE

[close]

p. 9

EC Executive Committee 7 EFMC YEARBOOK 2017 The Executive Committee (EC) consists of seven members: the President, the President Elect or the Past President, the Secretary, the Treasurer and three additional members. All members of the EC, except the President and the Past President, are elected by secret ballot by the Council during a meeting of the Council. After a term of one year, the President Elect will automatically become President. The members of the EC are not delegates of their respective countries. All details about the election process can be found in the statutes of the EFMC on the EFMC official website: www.efmc.info President President Elect Secretary Treasurer Member Member Prof. Dr Koen AUGUSTYNS University of Antwerp Medicinal Chemistry Campus Drie Eiken - Building A, Room 2.07 Universiteitsplein 1 - 2610 Antwerpen Belgium Tel: +32-3-265-27-17 - Fax: +32-3-265-27-39 Email: Koen.Augustyns@uantwerpen.be Dr Yves P. AUBERSON Novartis Global Discovery Chemistry, WKL-136.6.82 Klybeckstrasse 141 - Basel Switzerland Tel: +41-795939101 Email: yves.auberson@novarti.com Prof. Dr Anders KARLÈN Uppsala University Department of Medicinal Chemistry BMC Box 574 – Uppsala Sweden Tel : +46-701679177 – Fax: +46-184714474 Email : anders.karlen@orgfarm.uu.se Dr Pascal GEORGE Independent Scientific Expert & Adviser 11, Route de Rochefort 78730 Longvilliers France Tel: +33 673683384 Email: george.pascal@wanadoo.fr Prof. Dr Rui MOREIRA University of Lisbon – Faculty of Pharmacy Av. Prof. Gama Pinto - 1649-019 Lisbon Portugal Tel : +351-217946477 – Fax : +351-217946470 Email : rmoreira@ff.ul.pt Dr Antoni TORRENS Esteve R&D Center Parc Científic de Barcelona, Baldiri i Reixach 4, Barcelona, Spain Tel : +34-934466000 Email : atorrens@esteve.es Member Activities Dr Matthew TOZER Consultant & CSO AlgaeCytes Cambridge United Kingdom Email : matttozer@hotmail.com The current affairs of the Federation are handled by the EC. Among its members, the EC will assign the responsibilities of International Liaison, Communication and Planning.

[close]

p. 10

Council 8 Council The Council consists of the members of the EC and one delegate of each Adhering Organisation. According to the statutes, the voting rights are allotted according to the following rules: members of the EC: 1 vote, countries with up to 99 members: 2 votes, countries with 100-199 members: 3 votes, countries with 200-399 members: 4 votes, countries with 400-599 members: 5 votes, countries with 600-899 members: 6 votes, countries with more than 899 members: 7 votes. As for countries with more than one Adhering Organisation, votes will be proportionally distributed among them, taking into a resulting number will be rounded off to the closest digit. Dr David ALKER David Alker Associates - The Biological and Medicinal Chemistry Sector (BMCS) of the Royal Society of Chemistry (RSC), United Kingdom Dr Yves AUBERSON Novartis Institutes for BioMedical Research, Switzerland – EFMC Executive Committee Prof. Dr Koen AUGUSTYNS University of Antwerp, Belgium - EFMC Executive Committee Prof. Dr Sergey BACHURIN Institute of Physiologically Active Compounds - The D.I. Mendeleev Russian Chemical Society, Medicinal Chemistry Section, Russia Prof. Dr Bernd CLEMENT Kiel University - German Pharmaceutical Society, Section of Pharmaceutical/Medicinal Chemistry (DPhG), Germany Prof. Gabriele COSTANTINO Università degli Studi di Parma Division of Medicinal Chemistry of the Italian Chemical Society, Italy Prof. Dr Gunars DUBURS Latvian Institute of Organic Synthesis - Latvian Association for Medicinal Chemistry, Latvia Dr Vesna GABELICA MARKOVIC Galapagos - Croatian Chemical Society, Medicinal Chemistry Section, Croatia Prof. Pilar GOYA LAZA Instituto de Quimica Medica - Sociedad Española de Química Terapéutica, Spain Prof. Dr Miroslav J. GASIC Serbian Academy of Sciences and Arts - Serbian Chemical Society, Division of Medicinal Chemistry, Serbia Dr Pascal GEORGE Independent Scientific Expert & Adviser, France – EFMC Executive Committee Dr Georg JAESCHKE F. Hoffmann-La Roche - Division for Medicinal Chemistry & Chemical Biology (DMCCB), Switzerland Dr Annika JENMALM JENSEN Karolinska Institutet, Swedish Academy of Pharmaceutical Sciences, Sweden Prof. Dr Anders KARLÉN Uppsala University, Sweden - EFMC Executive Committee Prof. Dr Katarzyna KIEC-KONONOWICZ Jagiellonian University - Polish Society of Medicinal Chemistry, Poland Prof. Dr Danijel KIKELJ University of Ljubljana - Section for Medicinal Chemistry of the Slovenian Pharmaceutical Society, Slovenia Prof. Dr Thierry LANGER University of Vienna – Austrian Chemical Society, Medicinal Chemistry, Austria Dr Matilde MARQUES University of Lisbon - Division of Medicinal Chemistry of the Portuguese Chemical Society, Portugal Prof. Dr Emmanuel MIKROS Hellenic Society Of Medicinal Chemistry, Greece Dr Peter MOLENVELD Mercachem - Section Medicinal Chemistry, Royal Netherlands Chemical Society (KNCV), The Netherlands Prof. Dr Rui MOREIRA University of Lisbon - EFMC Executive Committee Dr Raphael NUDELMAN Teva Pharmaceutical Industries - Medicinal Chemistry Section of the Israel Chemical Society, Israel Prof. Dr Erhan PALASKA Hacettepe University – Turkish Association of Medicinal and Pharmaceutical Chemistry, Turkey Dr Laurent PROVINS UCB, Société Royale de Chimie (SRC), Medicinal Chemistry Division, Belgium Prof. Dr Jarkko RAUTIO University of Eastern Finland, Finnish Pharmaceutical Society, Finland Prof. Dr Janos SAPI University of Reims-Champagne-Ardenne – French Medicinal Chemical Society, France Prof. Dr Trond ULVEN University of Southern Denmark - The Danish Society of Pharmacology, Toxicology and Medicinal Chemistry, Denmark Dr Antoni TORRENS Esteve - EFMC Executive Committee, Esteve, Spain - EFMC Executive Committee Dr Matthew TOZER Consultant & CSO AlgaeCytes – EFMC Executive Committee Prof. Dr Serge VAN CALENBERGH Ghent University - Medicinal and Bioorganic Chemistry Division of Royal Flemish Chemical Society (KVCV), Belgium Dr Franz VON NUSSBAUM Bayer Pharma AG - Division of Medicinal Chemistry of the German Chemical Society (GDCh), Germany Prof. Dr János WÖLFLING University of Szeged - Organic and Medicinal Chemistry Division (OMCD) of the Hungarian Chemical Society (HCS), Hungary

[close]

p. 11

EFMC YEARBOOK 2017 Current Board Membership: • Uli STILZ – AB Chair • Annette G. BECK-SICKINGER • Stuart CONWAY • Frank LEEMHUIS • Karin BRINER • François DIEDERICH AB Advisory Board 9 Novo Nordisk, Denmark Leipzig University, Germany University of Oxford, United Kingdom Mercachem, The Netherlands Novartis, United States ETH Zürich, Switzerland The Advisory Board is an EFMC consulting body for the Executive Committee, assisting in assessing the Federation’s strategic goals. The tasks of the AB consist of: - advising on EFMC policy related matters internally and externally - proposing novel scientific or political initiatives to the Executive Committee - proposing strategies how to increase awareness of Medicinal Chemistry and support of the community in Europe - proposing strategies how to affect and interact with stakeholders in Europe The AB is composed of eminent scientists in the life sciences and medicinal chemistry and is chaired by the past president.

[close]

p. 12

EFMC Framework 10 EFMC Framework In February 2013, EFMC organised a workshop bringing together EFMC’s key stakeholders including the Council, the various committee members and the next generation of leaders, to engage in a dialogue about strategic initiatives EFMC needs to push to best serve the medicinal chemistry community in Europe and across the world. The stimulating discussions were very fruitful. Ideas came up, proposals were collected and working groups have been established, translating creativity and lateral-thinking into concreteness. As a result we established 8 working groups who were asked to come up with concrete proposals for implementation. The topics / working groups selected were: • EU Policy • Visibility of EFMC/Medicinal Chemistry • Social media • Interaction within the community • Young Scientist Meeting • Emerging markets • Links to other disciplines • Stakeholder map Working group progress has been reviewed in the meantime and overall the project teams made great progress. Already some of their proposals have been turned into concrete activities, some working groups are at the stage of prioritizing proposals for followup, and others have completed the activities and were closed. Below we provide you with an update on the progress made in 2016: 1 Strategic themes Influence on European science policy Current membership: • Anders Karlén (chair), Uppsala University, Sweden • Uli Stilz (EC sponsor), Novo Nordisk, Denmark • Rob Leurs (previous chair), VU University Amsterdam, The Netherlands • Christophe Genicot, UCB Biopharma, Belgium • Danijel Kikelj, University of Ljubljana, Slovenia • Phil Jones, European Screening Centre Newhouse, University of Dundee, UK EFMC started a collaboration with EuCheMS to be involved in European Policy. This collaboration took the form of a STOA Working Breakfast which took place on April 28, 2016 in Brussels and covered the topic: Solving Antimicrobial Resistance. Researchers and several Members of the European Parliament analysed the global challenge of antimicrobial resistance and weighted the pros and cons of possible solutions. Based on the success of this first STOA working breakfast, EFMC and EuCheMS will continue their partnership to further influence the European Science Policy. Visibility and recognition of medicinal chemistry Current membership: • Fabrizio Giordanetto (chair), Taros, Germany • Gabriele Costantino (EC sponsor), University of Parma, Italy • Laure Bouchez, Novartis, Switzerland • Bernd Clement, Kiel University, Germany • Vesna Gabelica Markovic, Galapagos, Croatia • David Rees, Astex Pharmaceuticals, UK • Henk Timmerman, VU University Amsterdam, The Netherlands • Anna Tsantili, University of Athens, Greece • Andrew Thomas, F. Hoffmann-La Roche, Switzerland The working group continued its constant effort to foster the visibility and recognition of Medicinal Chemistry and a Press Conference was hosted at the XXIV EFMC International Symposium on Medicinal Chemistry. During the Press Conference, four keynote speakers gave their view on the importance of the discipline and the key theme for this year: “MedChem impact/importance, collaborative nature of medicinal chemistry/ drug discovery”. At the occasion of the XXIV EFMC International Symposium on Medicinal Chemistry (EFMCISMC), a Public Engagement Event has also been organised in order to raise the awareness of the General Public on the research in the pharmaceutical industry. The event took place at the Manchester Museum of Science and Industry and took the format of an expert panel (Allan Jordan, Eric Kerran, Derek Lowe, Vicky Steadman) “pitching” for funding for key healthcare problems e.g cancer, infectious diseases, dementia. The best submissions of the “Why Medicinal Chemistry” Competition, held in 2015, were broadcasted in the EFMC Booth at the XXIV EFMC International Symposium on Medicinal Chemistry (EFMC-ISMC). All attendees could appreciate the successful attempt of the talented medicinal chemists to highlight what medicinal chemists do and why it is important. In 2017, the working group will continue emphasizing on targeting the broader public.

[close]

p. 13

11 EFMC YEARBOOK 2017 2 Operational activities Social media working group Current membership: • Stuart Conway, University of Oxford, UK • Koen Augustyns (EC member), University of Antwerp, Belgium EFMC continued being active on LinkedIn and Twitter (@EuroMedChem) and a specific LinkedIn group for the EFMC-ISMC Symposium series has been created (EFMC International Symposium on Medicinal Chemistry on LinkedIn). You are all invited to join the group to stay updated with the latest news concerning the EFMC International Symposium on Medicinal Chemistry. Communication team Current membership: • Gabriele Costantino, University of Parma, Italy • Brieuc Matagne, EFMC, Belgium EFMC has several communication tools which are running properly: the EFMC website, mass mailings to the database to promote EFMC organised and sponsored events, the electronic newsletter MedChemWatch, and the annual Yearbook. In 2016, the communication team continued managing those tools and further develop the EFMC newsletter. Short Courses team Current membership: • Peter Mohr, F. Hoffmann-La Roche, Switzerland • Henk Timmerman, VU University, The Netherlands • Serge Van Calenbergh, Ghent University, Belgium The team has selected topics for future editions of the EFMC Short Courses, and contacted potential course organisers. Info on the upcoming Short Courses can be found on the website www.efmcshortcourses.org Symposia EFMC International Symposium on Medicinal, EFMC Young Medicinal Chemist Symposium, EFMC International Symposium on Advances in Synthetic and Medicinal Chemistry. The meeting series “Frontiers in Medicinal Chemistry” have now been rebranded “ACSMEDI-EFMC Medicinal Chemistry Frontiers”. Each meeting will continue to be managed by dedicated organising committees. The President, Secretary and Secretariat oversee and coordinate the overall meeting planning. Grants EFMC supports the participation of young medicinal chemist to its symposiums by offering grants. The EFMC Council voted during the Council Meeting in Manchester in 2016 to increase and reshape the EFMC support to young medicinal chemist by now offering grants covering the complete registration for the EFMC International Symposium on Medicinal Chemistry (EFMC-ISMC), the EFMC International Symposium on Advances in Synthetic and Medicinal Chemistry (EFMC-ASMC) and the ACSMEDI-EFMC Medicinal Chemistry Frontiers Meeting. EFMC Sessions at symposia of related societies Current Membership: • Christian Ottmann (chair), Eindhoven University of Technology, The Netherlands • Koen Augustyns (EC sponsor), University of Antwerp, Belgium • Jordi Gràcia, Almirall, Spain • Sarah Skerratt, Pfizer, UK • Toni Torrens, Esteve, Spain • Rui Moreira, University of Lisbon, Portugal • Christa Müller, University of Bonn, Germany This operational team will assist the Executive Committee in identifying topics and chairs for EFMC organised sessions at symposia of related societies: ACS-MEDI, AFMC, CPA and EuCheMS. Links to other disciplines Current Membership: • Christian Ottmann (chair), Eindhoven University of Technology, The Netherlands • Yves Auberson, Novartis Institutes for BioMedical Research, Switzerland • Henk Timmerman, VU Amsterdam, The Netherlands Following the recommendations of the Advisory Board, the Executive Committee of the EFMC decided to reactivate this working group, transforming it into a task force that will have the goal to further explore collaboration with other learned societies of neighboring disciplines.

[close]

p. 14

MedChemWatch 12 MedChemWatch Editorial Committee • Gabriele COSTANTINO • Brieuc MATAGNE University of Parma, Italy EFMC, Belgium Established in 2007 as the official newsletter of EFMC, MedChemWatch has provided EFMC members with a regular and effective update on the activity of the Committees and Working Groups, and with information on EFMC-approved schools and EFMC meetings. Since 2010, MedChemWatch has been incorporated into the printed version of MedChemComm, thus broadening the potential audience. Each issue of MedChemWatch has been enriched by Perspective articles from leading scientists and by presentations of leading European laboratories of Medicinal Chemistry. Since January 2015, MedChemWatch continued serving our community in a different format, more tailored on the growing needs of rapid and short communication. The newsletter is delivered monthly, in a shorter format, with essential information on the activity of the EC/EFMC, news from the National Adhering Organisations and EFMC Partners, announcement of meetings and schools. Now more than ever the collaboration from the Member Societies and from individuals willing to contribute is essential to guarantee the widest information and mutual knowledge among medicinal chemists in Europe.

[close]

p. 15

Objectives EFMC Objectives 13 EFMC YEARBOOK 2017 The European Federation for Medicinal Chemistry (EFMC) is an independent association founded in 1970 that represents 25 scientific organisations from 23 European countries. Its objective is to advance the science of medicinal chemistry by promoting cooperation and encouraging strong links between the national adhering organisations in order to deepen contacts and exchanges between medicinal chemists in Europe and around the World. Moreover, it offers medicinal chemists the opportunity to present their work internationally by organising the biennial EFMC International Symposium on Medicinal Chemistry (EFMC-ISMC). These symposia, with an average attendance of 1.200 delegates, are highly international with a broad range of speakers and attendees from the pharmaceutical industry and academia. Furthermore, in collaboration with the Royal Society of Chemistry, EFMC is publishing MedChemComm, the official journal of EFMC. MedChemComm is a peer reviewed journal publishing concise articles and reviews covering medicinal chemistry research. The EFMC pursues its activities via flexible working groups, who cover strategic themes, themes for exploration, and operational tasks. An Advisory Board, composed of internationally highly recognized opinion leaders in the field of medicinal chemistry, assists in strategic planning and ensures a dynamic and vibrant advancement of EFMC. sia. EFMC is now a supporting member of the European Association for Chemical and Molecular Sciences (EuCheMS) and shares common interests with the European Federation for Pharmaceutical Sciences (EUFEPS). EFMC also reaches out to the Organic Synthesis community, through its successful series of EFMCASMC Symposia, organised with the support of ChemBridge Corporation and the National Adhering Organisations. Finally, the EFMC also collaborates with the Asian Federation of Medicinal Chemistry by participating in meetings organised by the AFMC and vice versa. Since autumn 2016, the EFMC also entered into a collaboration with the Chinese Pharmaceutical Association (CPA). An important part of the EFMC activities is the sponsorship of national scientific meetings and Medicinal Chemistry Schools and the funding of grants for younger scientists to attend EFMCISMC Symposia. The EFMC also acknowledges excellence in medicinal chemistry, by conferring three major awards: the Nauta Award on Pharmacochemistry, the UCB-Ehrlich Award for Excellence in Medicinal Chemistry and the Prous Institute-Overton and Meyer Award for New Technologies in Drug Discovery, which are given every two years for outstanding achievements in the field of Medicinal Chemistry. From 2010 on, EFMC established two new prizes to acknowledge the scientific accomplishments of young medicinal chemists, both in industry and academia. The EFMC has very strong links with the Medicinal Chemistry Division of the American Chemical Society. Through this collaboration the ACS organises sessions at the biennial EFMC-ISMC Symposia, and conversely the EFMC organises sessions at ACS National meetings. In addition, the two societies regularly exchange observers at their committee meetings and the EFMC has an ex officio representative on the Editorial Advisory Board of the Journal of Medicinal Chemistry. Also both societies jointly organise the ACSMEDIEFMC Medicinal Chemistry Frontiers sympo- The EFMC homepage is now connected to the websites of many national organisations, thus facilitating the flow of information. The monthly electronic newsletter MedChemWatch as well as the yearbook “Medicinal Chemistry in Europe” help to further develop cooperation between member organisations as well as their industrial partners and therefore advance medicinal chemistry in Europe, and by extension, around the globe. EFMC is also active on social media. To stay updated on EFMC activities, join the EFMC group on LindekIn or follow us on Twitter @EuroMedChem.

[close]

Comments

no comments yet